Journal of Radiation Research最新文献

Accelerated partial breast irradiation (APBI) is an alternative treatment for early-stage breast cancer. This study aimed to evaluate the effectiveness of the virtual bolus (VB) method and robust planning against respiratory motion in volumetric modulated arc therapy (VMAT)-APBI. VMAT plans were generated with 30 Gy in 5 fractions for 16 patients. Four treatment plans were developed and compared: a standard optimization (SO) plan without robust methods, a pseudo-skin flash strategy using a 5 mm VB (with densities of 0.4 and 1.0 g/cm3, VB04 and VB10), and a robust optimization (RO) plan to minimize penalties in worst-case scenarios. The isocenter was shifted 1-5 mm in each translational direction in robust analysis, and perturbed dose calculations were performed. All dose constraints for the target in SO and VB plans were within acceptable limits, but the dose evaluation volume V95% in the RO plan was lower than in other plans (P < 0.05). The clinical target volume V95% of the RO plan was significantly higher than in VB04 and VB10 (P < 0.05). The RO plan showed the best performance for organs at risk, followed by SO and VB plans, which resulted in higher doses. The RO plan exhibited the smallest change (±2%) in dose distribution due to respiratory motion. By contrast, the SO plan lacked robustness owing to absence of sufficient fluence in the air surrounding the planning target volume outside of the skin surface. The RO plan offers superior target coverage, maximum dose, and robustness compared to SO and VB methods.

Objective: To retrospectively analyze outcomes of patients who received definitive pelvic irradiation for clinically pelvic node-positive (cT1-4N1M0) prostate cancer (PCa).

Materials and methods: Clinical records of 148 patients with cT1-4N1M0 PCa treated with definitive pelvic radiotherapy (RT) between 2011 and 2015 were retrospectively collected from 25 institutions by the Japanese Radiation Oncology Study Group. The median age, initial prostate-specific antigen (PSA) level, and biologically effective dose (BED) to the prostate with α/β of 1.5 Gy were 69 (interquartile range [IQR], 65-74.3) years, 41.5 (IQR, 20.3-89) ng/ml, and 177.3 (IQR, 163.3-182) Gy, respectively. All patients underwent neoadjuvant androgen-deprivation therapy (ADT) for a median duration of 10 months. Most patients (141; 95.2%) received concurrent ADT during the irradiation period. The median duration of adjuvant ADT was 16 (IQR, 5-27.8) months. The Phoenix definition was used to assess biochemical failure.

Results: The median follow-up period was 53.5 months (IQR, 41-69.3). The 5-year overall survival (OS) probability was 86.8%. The 5-year biochemical failure-free survival and clinical progression-free survival rates were 69.6% and 76.3%, respectively. Multivariate analysis indicated the BED to the prostate to be a significant prognostic factor for OS. Regarding late adverse events, the estimated cumulative incidences of late Grade 2 or higher gastrointestinal and genitourinary toxicities at 5 years were 8.2% and 5.8%, respectively.

Conclusion: Long-term ADT combined with definitive pelvic external beam RT for cT1-4N1M0 PCa leaded to favorable outcomes. Future prospective studies should validate the suggested survival benefit of local dose escalation to the prostate in this cohort.

This study aimed to investigate the safety of combining radium-223 chloride (Ra-223) therapy with external beam radiation therapy (EBRT) for patients with multiple bone metastases from castration-resistant prostate cancer (CRPC), including lesions requiring urgent treatment such as those causing neurological symptoms due to spinal cord compression. We retrospectively analyzed data from patients with CRPC and bone metastases treated with Ra-223 therapy at our hospital between September 1, 2018, and December 31, 2023. Adverse events were evaluated using the Common Terminology Criteria for Adverse Events version 4.0. Of the 23 patients referred, data from 17 were included; 8 received concurrent Ra-223 therapy and EBRT, whereas others received only Ra-223 therapy. The median follow-up period was 20 months. Grade (G) 2 or higher adverse events occurred in seven patients (41.2%), and G 3 or higher in 2 (11.7%). None of the patients who received EBRT with fields involving the gastrointestinal tract experienced diarrhea, constipation, bleeding, perforation, or obstruction. Ra-223 therapy with EBRT did not increase adverse events compared with studies of Ra-223 therapy without EBRT. One case of G 5 Pneumocystis carinii pneumonia, likely because of steroid use for neurological symptoms and the patient's underlying diabetes mellitus, was noted. The effects of EBRT cannot be entirely excluded, so minimizing field size and dose is recommended when combining Ra-223 therapy and EBRT. Our findings indicate that concurrent Ra-223 therapy and EBRT could be safe for managing patients with symptomatic bone metastases and castration-resistant prostate cancer who require specialized treatment, provided sufficient attention is given to the field and the prescribed dose.

This study aimed to evaluate the prognostic value of pre-treatment blood cell counts in patients with brain metastasis (BM) from non-small cell lung cancer (NSCLC) who were treated using linear accelerator (linac)-based stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (fSRT) with a micro-multileaf collimator. Between January 2011 and November 2022, 271 consecutive patients underwent linac-based SRS/fSRT for BM from NSCLC. Thirty patients with insufficient blood test data during this period were excluded from this analysis. Thirty-five patients with steroid intake at the time point of the blood test and 18 patients with higher C-reactive protein were excluded. Thus, 188 patients were eventually enrolled in this study. The median follow-up period after SRS/fSRT was 21 months (range: 0-121 months), and the median survival time after SRS/fSRT was 19 months. Neutrophil-lymphocyte ratio ≥ 1.90, lymphocyte-monocyte ratio ≤ 1.67 and systemic inflammation response index (SIRI) ≥ 2.95 were unfavorable predictors of prognosis for patients who underwent SRS/fSRT for BM from NSCLC. Cox proportional-hazard multivariate analysis revealed that the SIRI was independent prognostic factors for increased risk of death. Thus, simple, less expensive, and routinely performed pre-treatment blood cell count measurements such as SIRI can predict the overall survival of patients treated with SRS/fSRT for BM from NSCLC.

Postoperative chemoradiotherapy (POCRT) is the standard treatment for patients with head and neck squamous cell carcinoma (HNSCC) with high-risk features (positive microscopic margins and/or extranodal extensions). We hypothesized that dose escalation using hyperfractionation in intensity-modulated radiotherapy (HF-IMRT) improves POCRT outcomes; however, no prospective trial has assessed the feasibility of POCRT in HF. Therefore, we evaluated the feasibility of POCRT using HF-IMRT. HNSCC patients with positive microscopic margins and/or extranodal extension following surgery were included. HF-IMRT (73.6 Gy in 64 fractions twice daily) was administered along with cisplatin at 40 mg/m2 once a week for seven cycles during radiotherapy. The primary endpoint was the proportion of patients who completed treatment, which included the planned radiotherapy and the administration of ≥200 mg/m2 of cisplatin. Feasibility was defined as the proportion of patients who completed treatment >60% using a one-sided binomial test. Ten patients were registered between October 2021 and April 2023. One patient was excluded because of tumor recurrence before POCRT. The median follow-up time was 18.2 months, and the proportion of patients who completed treatment was 88.9%. The median total dose of cisplatin was 240 mg/m2. The percentage of patients with grade 3 acute non-hematological adverse events was 77.8%. No patient experienced grade 4 or higher acute adverse events or grade 3 or higher late adverse events. POCRT using HF-IMRT is feasible for achieving adequate cisplatin doses and safe radiotherapy in patients with HNSCC.

Lung cancer is the most prevalent cancer worldwide, and radon exposure is ranked as the second risk factor after cigarette smoking. It has been reported that radon induces deoxyribonucleic acid damage and oxidative stress in cells. However, the protein profile and potential biomarkers for early detection of radon-induced lung cancer remain unknown. In this study, we aimed to investigate the effects of intermittent high-dose radon exposure on lung epithelial cells, analyze protein profiles and identify potential biomarkers for diagnosis of radon-related lung cancer. Human lung epithelial cells (A549) were exposed to radon (1000 Bq/m3) for 30 min daily for 7 days. Cell viability was measured using the WST-1 assay, and liquid chromatography-mass spectrometry proteomic analysis was performed. Differentially expressed proteins and gene ontology (GO) enrichment were analyzed. Our findings showed that intermittent high-radon exposure reduced A549 cell viability over time. Proteomic analysis identified proteins associated with stressed-induced apoptosis, mitochondrial adaptation, nuclear integrity and lysosomal degradation. These proteins are related to catabolism, stress response, gene expression and metabolic processes in the biological process of GO analysis. We highlighted specific proteins, including AKR1B1, CDK2, DAPK1, PRDX1 and ALHD2 with potential as biomarkers for radon-related lung cancer. In summary, intermittent high-dose radon exposure affects cellular adaptions of lung epithelial cells including stress-induced apoptosis, mitochondrial dysfunctions and immune regulation. The identified proteins may serve as diagnostic biomarkers or therapeutic targets for radon-related lung cancer.

Previous studies on cohorts of radiation workers have provided valuable insights into the effects of low-dose-rate radiation; however, some concerns regarding the potential confounding effects of smoking have been expressed. Although some studies have collected smoking data and adjusted for this variable, their limited numbers and the presence of other confounders obscure the extent of the impact of smoking on their results. To address this, we conducted a simulation study to quantitatively evaluate the bias from confounding and modeling conditions, similar to actual epidemiological studies. Our analysis, based on data from Japanese radiation workers, indicated that not adjusting for smoking can lead to an overestimation of radiation effects by approximately 110%. This overestimation was relatively insensitive to sample size and dose distribution parameters, but varied with radiation and smoking risk, baseline smoking probability, and heterogeneity in baseline risk. Considering the simplified settings of this simulation study and the uncertainty of the estimates of Japanese radiation workers, our simulation results were consistent with those of the real-world epidemiological study. We also compared the results using Cox and Poisson regression models, ensuring that their modeling approaches were as similar as possible, and found minimal differences between them.

High dose rate (HDR) intracavitary brachytherapy (ICBT) with a remote afterloading system plays a vital role in the treatment of cervical cancer. We aimed to develop a new verification system for ICBT for cervical cancer and evaluate the feasibility for clinical plans (PlanClin) generated for different remote afterloaders, applicators and treatment techniques. In total, 517 PlansClin of patients were treated with Elekta 192Ir microSelectron HDR v2r. Reference plans (PlanRef) were generated for the ICBT applicators. An equation to predict total dwell time (Tdwell) of PlanClin was generated by evaluating the relationship between the volume receiving 100% of the prescribed dose (V100%) and the Tdwell. We also developed software to detect human errors in PlanClin by comparing parameters, including applicator and reference point geometries, dwell position and weight patterns and reference point dose, with those of PlanRef. Feasibility was evaluated for 83 PlanClin cases treated with the Elekta Flexitron remote afterloader and six ICBT plans with extra catheters (hybrid BT). The linear fitting function showed good agreement with the correlation between V100% and Tdwell. The developed equation accurately estimated the Tdwell of the PlanClin treated with the Flexitron with an accuracy of 0.26 ± 0.49%. Our system successfully detected intentional human errors including incorrect channel mapping, applicator tip offset, incorrect plan templates, an applicator digitization model and incorrect reference points. A verification system based on PlanRef and a statistical approach is feasible for the new remote afterloaders, applicators and hybrid BT techniques. This system contributes to the implementation of safe treatments.